Login to Your Account

Ophthotech 'simply stunned' on failure of Fovista trials

By Peter Winter
BioWorld Insight Editor

Monday, December 12, 2016

New York-based Ophthotech Corp. saw its shares plummet 86.4 percent in heavy trading Monday on news that the pre-specified primary endpoint of mean change in visual acuity at 12 months, measured as BCVA in terms of additional letter gains, was not achieved.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription